Skip to main content

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.

See all publications
Not available in
This is not available in . You can go to the translated versions in these languages: